Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 232925-18-7
2. 2zrz4tsw3f
3. Methyl (2s)-2-[[[(2r,3s,5r)-5-[5-[(e)-2-bromoethenyl]-2,4-dioxopyrimidin-1-yl]-3-hydroxyoxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate
4. Nb-1011
5. L-alanine, N-(5-((1e)-2-bromoethenyl)-2'-deoxy-p-phenyl-5'-uridylyl)-, Methyl Ester
6. Bvdu Prodrug
7. (2s)-methyl 2-(((((2r,3s,5r)-5-(5-((e)-2-bromovinyl)-2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate
8. Brivudine Phosphoramidate
9. Unii-2zrz4tsw3f
10. Schembl13904642
11. Dtxsid00177862
12. 5-(2-bromovinyl)-2'-deoxy-5'-uridyl-phenyl-alanylphosphoramidate, Trans-
13. Db05116
14. (e)-5-(2-bromovinyl)-2'-deoxy-5'-uridyl Phenyl L-methoxyalaninylphosphoramidate
15. E-5-(2-bromovinyl)-2'-deoxyuridine-5'-(l-methylalaninyl)-phenylphosphoramidate
16. Hy-106168
17. Cs-0025066
18. J3.616.614b
19. Q7799611
20. (s)-2-({(2r,3s,5r)-5-[5-((e)-2-bromo-vinyl)-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-yl]-3-hydroxy-tetrahydro-furan-2-ylmethoxy}-phenoxy-phosphorylamino)-propionic Acid Methyl Ester
21. Methyl (2s)-2-[[[(2r,3s,5r)-5-[5-[(e)-2-bromovinyl]-2,4-dioxo-pyrimidin-1-yl]-3-hydroxy-tetrahydrofuran-2-yl]methoxy-phenoxy-phosphoryl]amino]propanoate
| Molecular Weight | 574.3 g/mol |
|---|---|
| Molecular Formula | C21H25BrN3O9P |
| XLogP3 | 1.1 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 11 |
| Exact Mass | 573.05118 g/mol |
| Monoisotopic Mass | 573.05118 g/mol |
| Topological Polar Surface Area | 153 Ų |
| Heavy Atom Count | 35 |
| Formal Charge | 0 |
| Complexity | 909 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 4 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in colorectal cancer.
NB1011 targets thymidylate synthase (TS), which catalyzes the transformation of E-5-(2-bromovinyl)-2'-deoxyuridine-5'-monophosphate (BVdUMP) into cytotoxic reaction products. Due to the elevated levels of TS expression in tumor cells compared to normal cells, these cytotoxic products are preferentially generated inside tumor cells, and, as expected, NB1011 is more toxic to cells with higher levels of TS expression. Therefore, NB1011 therapy should kill tumor cells without severely damaging normal cells.
ABOUT THIS PAGE
A Thymectacin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Thymectacin, including repackagers and relabelers. The FDA regulates Thymectacin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Thymectacin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Thymectacin supplier is an individual or a company that provides Thymectacin active pharmaceutical ingredient (API) or Thymectacin finished formulations upon request. The Thymectacin suppliers may include Thymectacin API manufacturers, exporters, distributors and traders.
Thymectacin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Thymectacin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Thymectacin GMP manufacturer or Thymectacin GMP API supplier for your needs.
A Thymectacin CoA (Certificate of Analysis) is a formal document that attests to Thymectacin's compliance with Thymectacin specifications and serves as a tool for batch-level quality control.
Thymectacin CoA mostly includes findings from lab analyses of a specific batch. For each Thymectacin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Thymectacin may be tested according to a variety of international standards, such as European Pharmacopoeia (Thymectacin EP), Thymectacin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Thymectacin USP).
LOOKING FOR A SUPPLIER?
